Targeting mTORC1 and AMPK Signaling: Potential Therapeutic Approaches for Idiopathic Pulmonary Fibrosis
Advances in World Medical Research · 2026
DOI: 10.71204/99f36029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in World Medical Research, 2026. Verfasst von Doudou Chen und 2 weiteren Autor:innen. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by increasing incidence and mortality. The underlying mechanisms of IPF remain poorly understood, contributing to the limited availability of effective treatments. Current therapies mainly slow disease progression but fail to provide a cure. Consequently, increasing attention has been directed toward modulating signaling pathways such as mammalian target of rapamycin complex 1(mTORC1) and Adenosine monophosphate–activated protein kinase (AMPK), both of which are key regulators of metabolic reprogramming in IPF. This review summarizes recent advances in therapeutic strategies that target cellular metabolism by modulating mTORC1 and AMPK.
Zitieren
APA
Chen, D., Liu, Y., & Xu, Z. (2026). Targeting mTORC1 and AMPK Signaling: Potential Therapeutic Approaches for Idiopathic Pulmonary Fibrosis. Advances in World Medical Research. https://doi.org/10.71204/99f36029
Vancouver
Chen D, Liu Y, Xu Z. Targeting mTORC1 and AMPK Signaling: Potential Therapeutic Approaches for Idiopathic Pulmonary Fibrosis. Advances in World Medical Research. 2026. doi:10.71204/99f36029
BibTeX
@article{Chen2026,
author = {Chen, Doudou and Liu, Yu and Xu, Zhihao},
title = {Targeting mTORC1 and AMPK Signaling: Potential Therapeutic Approaches for Idiopathic Pulmonary Fibrosis},
journal = {Advances in World Medical Research},
year = {2026},
doi = {10.71204/99f36029}
}
EUVIMED